MARSYAS II: last patient treated
The 120th patient was randomised in September and finalised the follow-up in December. The clinical trial has therefore been completed.
News
Approval of DSMB for Lead In-Phase and Go-Ahead for MARSYAS II Main Study
Aposcience AG received the Recommendations of the Data Safety Monitoring Board (DSMB). On 30 July 2021, three experts in the field of wound healing, after revising the data of the Lead In-Phase of the MARSYAS II trial (EudraCT…
Approval for clinical phase II study in DFU by German health agency PEI
On 27 May 2021 Aposcience AG received the notification of the Paul-Ehrlich-Institut of the approval of the clinical phase II trial in diabetic foot ulcer (DFU), MARSYAS II, for Germany. Currently, the MARSYAS II trial has…
Approval for clinical phase II study in DFU by Austrian health agency
Aposcience AG was granted approval by the Austrian health agency BASG to start a clinical phase II study in the indication diabetic foot ulcers of its novel product APOSEC, the secretome of stressed Peripheral Blood Mononuclear…
US Patent Office issues Allowance for APOSEC Patent
On Sept. 6, 2019, the United States Patent and Trademark Office issued a Notice of Allowance concerning the US patent application No. 13/140,120 “Pharmaceutical preparation”, the patent of APOSEC for the treatment of internal…
MarsyasI – clinical phase 1 study completed
Maryas I – clinical phase 1 study was completed on 5 February 2016
Paper on content analysis of APOSEC recently published
Beer L et al. Analysis of the Secretome of Apoptotic Peripheral Blood Mononuclear Cells: Impact of Released Proteins and Exosomes for Tissue Regeneration – was recently published in Scientific Reports. Sci Rep. 2015 Nov…
EPO intends to grant APOSEC patent for treatment of systemic conditions
The European Patent Office informed us its intention to grant our patent application for the treatment of systemic conditions with APOSEC.
APOSEC attenuates secondary damage following spinal cord injury
New Paper accepted in Experimental Neurology
Kickoff Meeting for Marsyas I Trial
On 23 Oct. 2014 the clinical phase I trial Marsyas I, a prospective, single-Center, randomised, double-blinded, placebo controlled, dose finding phase I study in the indication skin wound healing was initiated.
End of content
End of content